Revance Therapeutics, Inc. - Special Call Transcript
Welcome to the Revance Therapeutics call discussing the company's exclusive U.S. distribution agreement for TEOXANE's line of FDA-approved dermal fillers. (Operator Instructions) As a reminder, this conference is being recorded today, January 10, 2020.
I would now like to turn the conference over to Jeanie Herbert, Senior Director of Investor Relations. Please go ahead.
Thank you, Kevin. With me on today's call from Revance Therapeutics is President and Chief Executive Officer, Mark Foley; Chief Financial Officer, Toby Schilke; Chief Commercial Officer, Aesthetics and Therapeutics, Dustin Sjuts; and Vice President of Medical Affairs, Aesthetics and Therapeutics, Conor Gallagher.
This morning, Revance Therapeutics announced a transformative aesthetics portfolio transaction with TEOXANE SA for the exclusive U.S. distribution rights of TEOXANE's RHA range of FDA-approved dermal fillers. If you have not received this news release and would like to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |